Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Arnhem – page 50

787 clinical trials in Arnhem, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Arnhem at a glance
787
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

787 trials in Arnhem

Open in trial search

Colorectal cancer+1

Not recruiting

Study on Bevacizumab and Drug Combination for Patients with Resectable Colorectal Peritoneal Metastases

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Catharina Ziekenhuis Stichting

Ovarian cancer

Not recruiting

Study of olaparib, durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

Study on the Safety and Effectiveness of Pegcetacoplan for Patients with Post-Transplant Recurrence of C3 Glomerulopathy or Immune Complex Membranoproliferative Nephritis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Short-bowel syndrome

Not recruiting

Study on the Long-Term Safety and Effectiveness of Glepaglutide for Patients with Short Bowel Syndrome

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

Colorectal cancer

Not recruiting

Study of organ preservation using chemoradiotherapy and transanal surgery compared to standard surgery in patients with early rectal cancer (STAR-TREC trial)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:The University Of Birmingham

Study of Brentuximab Vedotin Combined with R-DHAP Chemotherapy for Patients with Relapsed or Treatment-Resistant CD30-Positive Diffuse Large B-Cell Lymphoma Who Are Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Prostate cancer

Not recruiting

Study of drug interactions between enzalutamide, morphine and edoxaban in patients with prostate cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Edoxaban
  • Sponsor:Radboud universitair medisch centrum Stichting

Diabetes mellitus+1

Not recruiting

Study on the Effectiveness of Oxygen Therapy for Patients with Diabetic Foot Ulcers

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Amsterdam UMC Stichting

Study on Rituximab for Patients with Relapsing Polymyalgia Rheumatica to Reduce Steroid Use

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Sint Maartenskliniek

Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Study on Lutetium (177Lu) Vipivotide Tetraxetan for Men with Progressive Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Novartis Pharma AG

Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Arnhem

What the registry says about research in the country

01 Oncology Studies

Innovative research focusing on advanced gastric cancer, bladder cancer, and various forms of leukemia. Studies include evaluation of novel imaging techniques and combination therapies for better treatment outcomes.

  • Gastric Cancer Staging
  • Bladder Cancer Therapeutics
  • Acute Myeloid Leukemia Treatment

Multiple trials exploring targeted therapies and innovative diagnostic approaches for various cancer types.

02 Cardiovascular Research

Comprehensive studies addressing cardiovascular disease management and prevention, including research on post-stroke care and cardiac arrest treatments.

  • Stroke Treatment Protocols
  • Cardiac Arrest Management
  • Cardiovascular Risk Reduction

Focus on improving patient outcomes through innovative therapeutic approaches and prevention strategies.

03 Metabolic Disorders

Clinical investigations targeting obesity and weight management, with emphasis on new therapeutic agents and their cardiovascular safety profiles.

  • Weight Management Therapies
  • Metabolic Disease Treatment
  • Safety Assessments

Evaluating novel approaches to treating metabolic disorders and their associated complications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.